SIGLEC9 and central nervous system cancer: As for the four subtypes, including classic, mesenchymal, and proneural subtypes, SIGLEC9 expression was higher in the mesenchymal subtype than in the other two subtypes of gliomas in TCGA database (Figure 1D).